A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: Long-term results

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Okkan, S ^a   Atkovar, G ^a   Sahinler, I ^a   Turkan, S ^a   Uzel, R ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cervix; Ornidazole; Radiosensitiser; Radiotherapy

Indexed keywords

BITOLTEROL MESILATE; ORNIDAZOLE; RADIOSENSITIZING AGENT;

ADULT; AGED; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA; ARTICLE; MIDDLE AGED; MORTALITY; SURVIVAL RATE; UTERINE CERVIX TUMOR;

ADULT; AGED; FEMALE; HUMANS; MIDDLE AGED; ORNIDAZOLE; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0029935945     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. BROWN JM. (1985). Sensitizers and protectors in radiotherapy. Cancer, 55, 2222-2228.
2. BUSH RS. (1986). The significance of anemia in clinical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 12, 2047-2050.
3. CIKARIC S. (1988). Radiation therapy of cervical carcinoma using either HDR or LDR afterloading. Comparison of 5-year results and complications. Strahlenther. Onkol., 82 (suppl.), 119-122.
4. DISCHE S. (1985). Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy, Radiother. Oncol., 3, 97-115.
5. DISCHE S. (1991). Radiotherapy and anaemia - the clinical experience. Radiother. Oncol., 20, (suppl.), 35-40.
6. DISCHE S, MACHIN D AND CHASSAGNE D. (1993). A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother. Oncol., 26, 93-103.
7. HAMBERGER AD, UNAL A, GERSHENSON DM AND FLETCHER GH. (1983). Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium. Int. J. Radiat. Oncol. Biol. Phys., 7, 367-371.
8. JOSLIN CAF, KILARA G AND KHOURY G. (1988). Influence of HDR fractions and dose on the 5-Year results and complications of cervix cancer. Strahlenther. Onkol., 82 (suppl.), 100-105.
9. KAPLAN EL AND MEIER P. (1958). Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
10. KUIPERS T. (1988). Dosimetry and complication rate in the treatment of cervix carcinoma with external irradiation and brachytherapy. Strahlenther. Onkol., 82 (suppl), 127-131.
11. LEIBEL S, BAUER M, WASSERMAN T, MARCIAL V, ROTMAN M, HORNBACK N, COOPER J, GILLESPIE B, PAKURIS E, CONNER N AND MARTIN-DURBIN L. (1987). Radiotherapy with or without misonidazole for patients with stage IIIb or stage IVa squamous cell carcinoma of the uterine cervix. Preliminary report of a Radiation Therapy Oncology Group's randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 13, 541-549.
12. MEDICAL RESEARCH COUNCIL. (1984). The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix: a report from the MRC Working Party on misonidazole for cancer of the cervix. Brit. J. Radiol., 57, 491-499.
13. OKKAN S AND UZEL R. (1982). The radiosensitizing effect of ornidazole in hypoxic mammalian tissue: an in vivo study. Int. J. Radiat. Oncol. Biol. Phys., 8, 1735-1739.
14. OKKAN S, YAZICI Z, UZEL R, AKCASU A, TURKAN S, HACIBEKIROGLU M, OLGUN P AND EGEHAN I. (1986). Use of ornidazole in fractionated radiotherapy: dose tolerance, serum and tumour tissue concentration. Radiother. Oncol., 5, 295-301.
15. OKKAN S, UZEL R, YAZICI Z, TURAN N, AKCASU A, TURKAN S AND HACIBEKIROGLU M. (1989). Use of ornidazole as a radiosensitizer on fractionated irradiation : results of clinical trials. In Improvement of Cancer Therapy by the Combination of Conventional Radiation and Chemical or Physical Means, pp. 105-122. IAEA-TECDOC-493: Vienna.
16. ORTON CG, SEYEDSADR M AND SOMNAY A. (1991). Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int. J. Radiat. Oncol. Biol. Phys., 21, 1425-1434.
17. OVERGAARD J, BENTZEN SM, KOLSTAD P, KJOERSTAD K, DAVY M, BERTELSEN K, MANTYLA M, FRANKENDAL B, SKRYTEN A, LÖFTQUIST I, PEDERSEN M, SELL A AND HAMMER R. (1989). Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol.Phys., 16, 1069-1072.
18. PATEL FD, SHARMA SC, NEGI PS, GHOSHAL S AND GUPTA BD. (1994). Low dose rate vs high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int. J. Radiat. Oncol. Biol. Phys., 28, 335-341.
19. PEREZ CA, BREAUX S, BEDWINEK JM, MADOC-JONES H, CAMEL HM, PURDY JA AND WALZ BJ. (1984). Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of Complications. Cancer, 54, 235-246.
20. PEREZ CA. (1992). Uterine cervix. In Principles and Practice of Radiation Oncology, Perez CA and Brady LW. (eds) pp. 1143-1202. JB Lippincott: Philadelphia.
21. PETO R, PIKE MC, ARMITAGE P, BRESLOW NE, COX DR, HOWARD SV, MANTEL N, MCPHERSON K, PETO J AND SMITH PG. (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35, 1-39.
22. SELKE P, ROMAN TN, SOUHAMI L, FREEMAN CR, CLARK BG, EVANS MD, PLA C AND PODGORSAK EB. (1993). Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys., 27, 800-809.
23. SHERRAH-DAVIES E. (1985). Morbidity following low dose rate selection therapy for cervical cancer. Clin. Radiol., 36, 131-140.
24. STEHMAN FB, BUNDY BN, THOMAS G, KEYS HM, d'ABLAING G, FOWLER WC, MORTEL R AND CREASMAN WT. (1993). Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J. Clin. Oncol., 11, 1523-1528.
25. URTASUN RC, BAND P, CHAPMAN JD, FELDSTEIN ML, MIELKE B AND FRYER, C. (1976). Radiation and high-dose metronidazole in supratentorial glioblastoma. N. Engl. J. Med., 294, 1364-1367.
26. UZEL R. (1980). High dose-rate intracavitary irradiation for the treatment of carcinoma of the cervix at the University of Istanbul. Br. J. Radiol. (Special report), 17, 111-116.
27. UZEL R, OKKAN S, TÖRE G AND KOCA S. (1988). Results and complications of high dose rate intracavitary radiotherapy compared with conventional dose rate in carcinoma of the cervix. Strahlenther. Onkol. 82, (suppl.), 132-136.
28. WAHRSON H AND RÖMER G. (1988). 5-year results with HDR afterloading in cervix cancer: dependence on fractionation and dose. Strahlenther. Onkol., 82 (suppl.), 139-146.
29. WATSON ER, HALNAN KE, DISCHE S, SAUNDERS MI, CADE IS, MCEWEN JB, WIERNIK G, PERRINS JD AND SUTHERLAND I. (1978). Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br. J. Radiol., 51, 879-887.